Bridge Biotherapeutics Inc., a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June 5 - 8, 2023.

Pavel Printsev, Director of Business Development, will provide an up-to-date company overview as well as an introduction to its clinical-stage assets

Oncology: BBT-176 and BBT-207 (Fourth-generation EGFR TKIs for non-small cell lung cancer active against C797S resistance mutations)

Pulmonology: BBT-877 (Autotaxin inhibitor for idiopathic pulmonary fibrosis)

Earlier this year, the company announced its acquisition of a diagnostics company with a novel biosensing technology. The company presentation is expected to include an introduction to the newly acquired biosensing technology and commercial prospects.

'We are pleased to share the progress of clinical assets as well as new business activities through an in-person presentation at this year's BIO International conference, following last year's event. We look forward to advancing our novel research and development pipeline with a strong focus on oncology and pulmonology,' stated Pavel Printsev, Director of Business Development of Bridge Biotherapeutics.

(C) 2023 Electronic News Publishing, source ENP Newswire